SCHEMBL1745362

SCHEMBL1745362

COC(=O)CCc1ccc(OCc2cccc(CN(C)c3nc(-c4ccccc4)cs3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.48
FFAR1 O14842 11/20 0.48
FFAR4 Q5NUL3 3/20 0.48
AKR1B1 P15121 1/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
MAPT P10636 2/20 0.46
VDR P11473 1/20 0.45
PPARD Q03181 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GSTO1 P78417 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1746563 0.94 KMT2A (0.49) NPSR1FFAR1FFAR4KMT2AMEN1
SCHEMBL1746853 0.93 FFAR1 (0.57) FFAR1FFAR4AKR1B1
SCHEMBL3911602 0.90 NPSR1 (0.51) NPSR1FFAR1FFAR4AKR1B1KMT2A
SCHEMBL1744670 0.85 FFAR1 (0.57) NPSR1FFAR1FFAR4AKR1B1KMT2A
SCHEMBL3917024 0.85 NPSR1 (0.53) NPSR1FFAR1FFAR4KMT2AMEN1
SCHEMBL1746617 0.85 KMT2A (0.50) NPSR1FFAR1FFAR4KMT2AMEN1
SCHEMBL4029428 0.84 KMT2A (0.51) NPSR1KMT2AMEN1MAPTL3MBTL1
SCHEMBL1745444 0.83 KMT2A (0.48) NPSR1FFAR1KMT2AMEN1MAPT
SCHEMBL1747402 0.82 FFAR1 (0.48) NPSR1FFAR1FFAR4KMT2AMEN1
SCHEMBL3918017 0.82 FFAR1 (0.57) FFAR1FFAR4AKR1B1PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR NPSR1 132/4885FFAR1 33/4885FFAR4 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.